Otros idiomas Virax Biolabs Group Limited

Acciones

VRAX

KYG9495L1335

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 10/07/2026			Variación 5 días	Varia. 1 de enero.
4,080 ^USD	-35,85 %		+30,35 %	-52,81 %

10/07	Principales caídas de la media sesión	MT
10/07	Principales caídas antes de la apertura	MT

Otros idiomas

10/07	Virax Biolabs : Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
10/07	Top Midday Decliners
10/07	Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
10/07	Top Premarket Decliners
06/07	Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2026
06/07	Virax Biolabs : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
06/07	Virax Biolabs Group Limited Auditor Raises 'Going Concern' Doubt
24/06	Virax Biolabs to Implement 1-for-25 Share Consolidation
24/06	Virax Biolabs : Announces 1-for-25 Share Consolidation
27/05	Stocks Under $1: NXXT, TOON, VRAX, AIM, SBFM on Breakout Watch
26/05	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes
15/05	Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
14/04	Virax Biolabs : Investor Presentation (Virax Biolabs Investor Deck Q2 2026)
31/03	Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
18/03	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association
04/12	Virax Biolabs : Announces Closing of $5 Million Private Placement
04/12	Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
04/12	Virax Biolabs Group Limited announced that it has received $4.99875 million in funding
03/12	Virax Biolabs : Announces $5 Million Private Placement
03/12	Virax Biolabs Group Limited Announces $5 Million Private Placement
03/12	Virax Biolabs' : CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
03/12	Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
03/12	Virax Biolabs Group Limited announced that it expects to receive $4.99875 million in funding
02/12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2025
03/11	Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes